Free Trial
→ Tesla. SolarCity. Twitter. This $4 stock is next. (From Behind the Markets) (Ad)tc pixel Free TBIO Stock Alerts

Telesis Bio (TBIO) Competitors

Telesis Bio logo
Compare

TBIO vs. SMIT, SPEC, THMO, HTGMQ, and OLITW

Should you buy Telesis Bio stock or one of its competitors? MarketBeat compares Telesis Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Telesis Bio include Schmitt Industries (SMIT), Spectaire (SPEC), ThermoGenesis (THMO), HTG Molecular Diagnostics (HTGMQ), and OmniLit Acquisition (OLITW). These companies are all part of the "measuring and control equipment" industry.

How does Telesis Bio compare to Schmitt Industries?

Telesis Bio (NASDAQ:TBIO) and Schmitt Industries (NASDAQ:SMIT) are both measuring and control equipment companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Schmitt Industries has lower revenue, but higher earnings than Telesis Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A
Schmitt Industries$9.89M0.01-$3.28MN/AN/A

Schmitt Industries has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company Net Margins Return on Equity Return on Assets
Telesis Bio-336.59% N/A -61.89%
Schmitt Industries N/A N/A N/A

Telesis Bio has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market. Comparatively, Schmitt Industries has a beta of 0.11, indicating that its stock price is 89% less volatile than the broader market.

37.6% of Telesis Bio shares are held by institutional investors. 24.5% of Telesis Bio shares are held by insiders. Comparatively, 17.1% of Schmitt Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Telesis Bio's average media sentiment score of 0.00 equaled Schmitt Industries'average media sentiment score.

Company Overall Sentiment
Telesis Bio Neutral
Schmitt Industries Neutral

Summary

Telesis Bio beats Schmitt Industries on 4 of the 7 factors compared between the two stocks.

How does Telesis Bio compare to Spectaire?

Telesis Bio (NASDAQ:TBIO) and Spectaire (NASDAQ:SPEC) are both measuring and control equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Telesis Bio's average media sentiment score of 0.00 equaled Spectaire'saverage media sentiment score.

Company Overall Sentiment
Telesis Bio Neutral
Spectaire Neutral

Spectaire has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%. Telesis Bio's return on equity of 0.00% beat Spectaire's return on equity.

Company Net Margins Return on Equity Return on Assets
Telesis Bio-336.59% N/A -61.89%
Spectaire N/A -81.22%304.57%

Telesis Bio has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market. Comparatively, Spectaire has a beta of -6.36, meaning that its share price is 736% less volatile than the broader market.

37.6% of Telesis Bio shares are held by institutional investors. Comparatively, 26.5% of Spectaire shares are held by institutional investors. 24.5% of Telesis Bio shares are held by company insiders. Comparatively, 25.4% of Spectaire shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Spectaire has lower revenue, but higher earnings than Telesis Bio. Spectaire is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A
SpectaireN/AN/A$8.95M-$0.30N/A

Summary

Telesis Bio and Spectaire tied by winning 5 of the 10 factors compared between the two stocks.

How does Telesis Bio compare to ThermoGenesis?

Telesis Bio (NASDAQ:TBIO) and ThermoGenesis (NASDAQ:THMO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, Telesis Bio's average media sentiment score of 0.00 equaled ThermoGenesis'average media sentiment score.

Company Overall Sentiment
Telesis Bio Neutral
ThermoGenesis Neutral

37.6% of Telesis Bio shares are held by institutional investors. Comparatively, 5.8% of ThermoGenesis shares are held by institutional investors. 24.5% of Telesis Bio shares are held by insiders. Comparatively, 78.0% of ThermoGenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Telesis Bio has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market. Comparatively, ThermoGenesis has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

ThermoGenesis has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company Net Margins Return on Equity Return on Assets
Telesis Bio-336.59% N/A -61.89%
ThermoGenesis N/A N/A N/A

ThermoGenesis has lower revenue, but higher earnings than Telesis Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A

Summary

ThermoGenesis beats Telesis Bio on 5 of the 9 factors compared between the two stocks.

How does Telesis Bio compare to HTG Molecular Diagnostics?

HTG Molecular Diagnostics (NASDAQ:HTGMQ) and Telesis Bio (NASDAQ:TBIO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

HTG Molecular Diagnostics has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company Net Margins Return on Equity Return on Assets
HTG Molecular DiagnosticsN/A N/A N/A
Telesis Bio -336.59%N/A -61.89%

HTG Molecular Diagnostics has higher earnings, but lower revenue than Telesis Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HTG Molecular Diagnostics$6.37M0.00-$21.59M-$2.28N/A
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A

HTG Molecular Diagnostics has a beta of 3.06, suggesting that its stock price is 206% more volatile than the broader market. Comparatively, Telesis Bio has a beta of 2.27, suggesting that its stock price is 127% more volatile than the broader market.

In the previous week, HTG Molecular Diagnostics' average media sentiment score of 0.00 equaled Telesis Bio'saverage media sentiment score.

Company Overall Sentiment
HTG Molecular Diagnostics Neutral
Telesis Bio Neutral

37.6% of Telesis Bio shares are owned by institutional investors. 2.6% of HTG Molecular Diagnostics shares are owned by insiders. Comparatively, 24.5% of Telesis Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

HTG Molecular Diagnostics beats Telesis Bio on 5 of the 9 factors compared between the two stocks.

How does Telesis Bio compare to OmniLit Acquisition?

OmniLit Acquisition (NASDAQ:OLITW) and Telesis Bio (NASDAQ:TBIO) are both measuring and control equipment companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

OmniLit Acquisition has higher earnings, but lower revenue than Telesis Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OmniLit AcquisitionN/AN/AN/AN/AN/A
Telesis Bio$225.09M0.00-$47.72M-$20.52N/A

37.6% of Telesis Bio shares are held by institutional investors. 24.5% of Telesis Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

OmniLit Acquisition has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%.

Company Net Margins Return on Equity Return on Assets
OmniLit AcquisitionN/A N/A N/A
Telesis Bio -336.59%N/A -61.89%

In the previous week, OmniLit Acquisition's average media sentiment score of 0.00 equaled Telesis Bio'saverage media sentiment score.

Company Overall Sentiment
OmniLit Acquisition Neutral
Telesis Bio Neutral

Summary

Telesis Bio beats OmniLit Acquisition on 3 of the 5 factors compared between the two stocks.

Get Telesis Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TBIO vs. The Competition

Export
MetricTelesis BioAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market CapN/AN/A$6.46B$11.98B
Dividend YieldN/AN/A2.67%5.55%
P/E Ratio0.00N/A23.8523.62
Price / SalesN/A0.00512.48110.29
Price / CashN/AN/A26.9937.25
Price / BookN/A0.0010.276.66
Net Income-$47.72M-$47.72M$3.57B$337.72M

Telesis Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TBIO
Telesis Bio
N/AN/AN/AN/A$0.00$225.09MN/A200
SMIT
Schmitt Industries
N/A$0.02
flat		N/AN/A$57K$9.89MN/A160
SPEC
Spectaire
N/A$0.00
flat		N/AN/A$9KN/AN/A8
THMO
ThermoGenesis
N/A$0.00
flat		N/AN/A$1K$9.61MN/A40
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/AN/A$0.00$6.37MN/A90

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TBIO) was last updated on 6/8/2026 by MarketBeat.com Staff.
From Our Partners
This ‘Starburst’ Could Be Bigger Than the SpaceX IPO
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
How to get into the SpaceX IPO before June 12
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel
After “33X” call, Jon Najarian reveals NEW Tesla prediction…
Jon Najarian called Tesla a buy in 2014 before the stock climbed as high as 3,392%. He also called Palantir on...
Banyan Hill Publishing | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Trump’s secret China deal
Trump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...
Porter & Company | Sponsoredtc pixel
I paid $5,000 to hear Elon say this
One investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...
InvestorPlace | Sponsoredtc pixel